MedTrace Logo

DURAFIBER Ag Post-Market Clinical Follow-Up

NCT03277131 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-03-02

No results posted yet for this study

Summary

The aim of the study is to evaluate the performance of DURAFIBER Ag and to assess how many bacteria are present in infected wounds over an 8 week period.

Conditions

  • Wounds and Injuries
  • Venous Leg Ulcer
  • Infection

Interventions

DEVICE

DURAFIBER Ag

DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing

Sponsors & Collaborators

  • Smith & Nephew, Inc.

    lead INDUSTRY

Principal Investigators

  • Helen Fearnley · Bradford Teaching Hospitals NHS Foundation Trust

  • Elizabeth Huddleston, PhD · Smith & Nephew - Global Strategy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-12
Primary Completion
2019-06-19
Completion
2019-06-19

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03277131 on ClinicalTrials.gov